Skip to main content
. 2021 Jun 3;151(8):2236–2244. doi: 10.1093/jn/nxab142

TABLE 2.

Patient characteristics1

Demographics Frequency, n (%)
Sex
 Male 30 (47.6)
 Female 33 (52.4)
Age, y
 <70 21 (33.3)
 ≥70 42 (66.7)
Ethnicity
 White 59 (93.7)
 Other 4 (6.3)
BMI, kg/m2
 ≥25 31 (49.2)
 ≥30 15 (23.8)
Smoking status
 Current 10 (15.9)
 Ex 28 (44.4)
 Never 25 (39.7)
Alcohol excess history
 Yes 11 (17.5)
 No 52 (82.5)
Clinical frailty
 Yes 45 (71.4)
 No 16 (25.4)
 Not recorded 2 (3.2)
Comorbidities
  Liver disease
  Yes 6 (9.5)
  No 57 (90.5)
  Hypertension
  Yes 34 (53.1)
  No 29 (45.3)
  Heart failure
  Yes 8 (12.7)
  No 55 (87.3)
  T2DM
  Yes 18 (28.1)
  No 45 (70.3)
  Chronic renal failure
  Yes 11 (17.5)
  No 52 (82.5)
  Asthma
  Yes 13 (20.6)
  No 50 (79.4)
  COPD
  Yes 14 (22.2)
  No 49 (77.8)
  Active cancer
  Yes 11 (17.5)
  No 52 (82.5)
CT imaging
 Thorax, abdomen, and pelvis 48 (76.2)
 Abdomen and pelvis only 15 (23.8)
Inflammatory status
 CRP, mg/L
  ≥10 52 (82.5)
  ≥80 31 (49.2)
  ≥150 14 (22.2)
 Albumin, g/L
  <25 13 (20.6)
  ≥25 50 (79.4)
 NLR
  <3 10 (15.6)
  3–5 12 (18.8)
  >5 41 (64.1)
 poGPS
  0 41 (65.1)
  1–2 22 (34.9)
Primary outcomes
  ITU admission
  Yes 3 (4.8)
  No 60 (95.2)
  30-d mortality
  Yes 11 (17.5)
  No 52 (82.5)

1COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computed tomography; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow Prognostic Score; T2DM, type 2 diabetes mellitus.